Fig. 3.

Efficacy analysis of atezo/bevvs.lenvatinib in first-line therapy.

(A) mOS, (B) mPFS, and (C) best response according to local investigator evaluation were assessed in patients receiving either atezo/bev or lenvatinib in the first-line situation. Kaplan–Meier analysis was performed to calculate the median survival. Survival was compared using the log-rank test. Fisher’s exact test was used to compare response rates. atezo/bev, atezolizumab/bevacizumab; CR, complete response; DCR, disease control rate; HR, hazard ratio; mOS, median overall survival; mPFS, median progression-free survival; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.